GlassScriptPhysician profile
Mohan Lal Gupta
NPI 1295791994
$4,256.32
in general payments reported to CMS, 2019-2025
30 companies · $898 in 2025
The $898 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $362 · 2021: $634 · 2022: $832 · 2023: $583 · 2024: $273 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.71 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $849.96 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $707.36 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $400.74 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $398.98 | 2019-2022 | |
| Pfizer INC. | $329.02 | 2019-2025 | |
| Madrigal Pharmaceuticals | $161.27 | 2025 | Rezdiffra |
| Novo Nordisk INC | $146.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.84 | 2019-2025 | Jardiance |
| Galderma Laboratories, L.P. | $125.00 | 2025 | Nemluvio |
| Bayer Healthcare Pharmaceuticals INC. | $106.92 | 2021-2025 | |
| Ortho-Clinical Diagnostics, INC. | $100.72 | 2024 | |
| Genzyme Corporation | $98.33 | 2025 | |
| Mylan Specialty L.P. | $91.59 | 2020 | |
| Amarin Pharma, INC. | $65.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $65.15 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.30 | 2019-2020 | |
| Optinose US, INC. | $46.96 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.95 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $43.08 | 2024-2025 | Voquezna |
| Dexcom, INC. | $41.16 | 2022-2025 | Dexcom G6 Transmitter |
| Heartflow, INC. | $37.25 | 2022 | |
| Hologic Sales and Service, LLC | $35.89 | 2025 | Aptima |
| Janssen Biotech, INC. | $30.64 | 2025 | Tremfya, Stelara, Simponi |
| Lexicon Pharmaceuticals, INC. | $28.88 | 2023 | Inpefa |
| Abbott Laboratories | $23.81 | 2022 | |
| Almatica Pharma LLC | $22.66 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Boston Scientific Corporation | $21.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.38 | 2023 | Eliquis |
| Abbvie INC. | $18.89 | 2025 | |
| Arbor Pharmaceuticals, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.